Oral biologics Target clinics and partners with interest in oral biologic therapeutics for autoimmune, metabolic, and inflammatory diseases, highlighting AMT’s GI-selective delivery platform and potential superiority in efficacy and tolerability versus systemic biologics.

UC focus Prioritize opportunities around ulcerative colitis, leveraging AMT-101’s Phase 1b data and gut-localized IL-10 mechanism to position as a differentiated therapy with reduced systemic exposure.

Private-public IP Emphasize a broad global IP portfolio and platform-protected approach to reduce competitive risk, appealing to licensing partners and potential acquirers seeking defensible, long-term asset value.

Strategic partnerships Leverage recent merger activity and leadership profiles to pursue co-development, co-commercialization, or strategic investment discussions with biotech and pharma firms seeking late-stage or platform-based opportunities.

Clinical pipeline Highlight AMT’s pipeline breadth and Phase 1b/2 stage assets to identify cross-therapeutic expansion opportunities, companion diagnostic collaborations, and payer-focused value propositions for precision GI therapies.